These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 17043014)

  • 1. Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study.
    Moser EC; Noordijk EM; van Leeuwen FE; Baars JW; Thomas J; Carde P; Meerwaldt JH; van Glabbeke M; Kluin-Nelemans HC
    Haematologica; 2006 Nov; 91(11):1481-8. PubMed ID: 17043014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study.
    Sacchi S; Marcheselli L; Bari A; Marcheselli R; Pozzi S; Luminari S; Lombardo M; Buda G; Lazzaro A; Gobbi PG; Stelitano C; Morabito F; Quarta G; Brugiatelli M
    Haematologica; 2008 Mar; 93(3):398-404. PubMed ID: 18268277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcome of localized high-grade non-Hodgkin's lymphoma treated with high dose CHOP regimen and involved field radiotherapy: results of a GOELAMS study.
    Bernard M; Cartron G; Rachieru P; LeMevel A; Branger B; Le Maignan C; Berthou C; Ghandour C; Delwail V; Milpied N; Cassasus P; Celigny PS; Guyotat D; Lamy T; Desablens B;
    Haematologica; 2005 Jun; 90(6):802-9. PubMed ID: 15951293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
    Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
    Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
    Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
    Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
    Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
    Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second primary neoplasms following non-Hodgkin's lymphoma in New South Wales, Australia.
    Brennan P; Coates M; Armstrong B; Colin D; Boffetta P
    Br J Cancer; 2000 Apr; 82(7):1344-7. PubMed ID: 10755412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Survival of patients with aggressive non-hodgkin's lymphoma: no difference between first line treatment in a prospective randomised phase III clinical trial and first line treatment according to routine clinical practice].
    van Agthoven M; Wittebol S; Budel LM; Uyl-de Groot CA; Kramer MH
    Ned Tijdschr Geneeskd; 2004 Jan; 148(2):88-93. PubMed ID: 14753131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High incidence of secondary myelodysplastic syndromes following PROMACE-MOPP and involved field radiotherapy for localized gastric non-Hodgkin's lymphomas.
    Corti C; Theodore C; Bayle C; Rougier P; Nasr F; Cosset JM; Girinsky T; Hayat M; Ribrag V
    Hematol Oncol; 1996 Dec; 14(4):159-63. PubMed ID: 9267461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of second malignant neoplasms after childhood leukemia and lymphoma: an international study.
    Maule M; Scélo G; Pastore G; Brennan P; Hemminki K; Tracey E; Sankila R; Weiderpass E; Olsen JH; McBride ML; Brewster DH; Pompe-Kirn V; Kliewer EV; Chia KS; Tonita JM; Martos C; Jonasson JG; Merletti F; Boffetta P
    J Natl Cancer Inst; 2007 May; 99(10):790-800. PubMed ID: 17505074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Preliminary outcome for patients with relapsed or resistant advanced non-Hodgkin's lymphoma treated by EPOCH regimen].
    Huang HQ; Jiang WQ; Wang W; Zhou ZM; Xia ZJ; Lin XB; Li YH; Xu RH; Zhang L; Xu GC; Sun XF; Liu DG; He YJ; Guan ZZ
    Ai Zheng; 2003 Apr; 22(4):389-92. PubMed ID: 12703995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study.
    Schaapveld M; Visser O; Louwman MJ; de Vries EG; Willemse PH; Otter R; van der Graaf WT; Coebergh JW; van Leeuwen FE
    J Clin Oncol; 2008 Mar; 26(8):1239-46. PubMed ID: 18323547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of involved field radiotherapy in partial response after doxorubicin-based chemotherapy for advanced aggressive non-Hodgkin's lymphoma.
    Moser EC; Kluin-Nelemans HC; Carde P; Meerwaldt JH; Tirelli U; Aleman BM; Baars J; Thomas J; van Glabbeke M; Noordijk EM
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1168-77. PubMed ID: 16887289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma.
    Schenkein DP; Roitman D; Miller KB; Morelli J; Stadtmauer E; Pecora AL; Cassileth P; Fernandez H; Cooper BW; Kutteh L; Lazarus HM
    Biol Blood Marrow Transplant; 1997 Oct; 3(4):210-6. PubMed ID: 9360783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Second neoplasms as a late complication of the treatment of Hodgkin's disease].
    Morales MD; González FA; Villegas A; del Potro E; Díaz Mediavilla J; Martínez R; Alvarez A; Colomé JA
    Sangre (Barc); 1992 Dec; 37(6):429-33. PubMed ID: 1293793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-Hodgkin's lymphoma in the elderly: the impact of advanced age on therapeutic options and clinical results.
    Orlandi E; Lazzarino M; Brusamolino E; Castelli G; Pagnucco G; Morra E; Bernasconi C
    Haematologica; 1991; 76(3):204-8. PubMed ID: 1743590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts.
    Huang KP; Weinstock MA; Clarke CA; McMillan A; Hoppe RT; Kim YH
    Arch Dermatol; 2007 Jan; 143(1):45-50. PubMed ID: 17224541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
    Harrison CN; Gregory W; Hudson GV; Devereux S; Goldstone AH; Hancock B; Winfield D; MacMillan AK; Hoskin P; Newland AC; Milligan D; Linch DC
    Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma.
    Brown JR; Yeckes H; Friedberg JW; Neuberg D; Kim H; Nadler LM; Freedman AS
    J Clin Oncol; 2005 Apr; 23(10):2208-14. PubMed ID: 15753460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.